TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
1.900
+0.030 (1.60%)
Oct 6, 2026, 11:27 AM EDT - Market open
TuHURA Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, share issuance, executive compensation, and auditor ratification, with all proposals approved by stockholders. No questions were raised, and the Board's recommended three-year frequency for compensation votes was adopted.
-
The company is advancing a phase III trial for frontline Merkel cell carcinoma with FDA support, targeting accelerated approval and leveraging novel immunotherapy platforms. Additional programs include a VISTA-inhibiting antibody for AML and innovative ADCs, with key data and regulatory milestones expected within the next year.